Dr. Thomas Jung, M.D., Ph.D. has been Chief Development Officer of Auris Medical Holding AG since September 01, 2016. Dr. Jung leads the Auris Medical Holding's clinical, preclinical and pharmaceutical development activities. Dr. Jung served as Chief Medical Officer of Cell Medica Switzerland AG since September 1, 2011. Dr. Jung has significant experience in medical research and clinical development. Prior to joining Auris Medical, Dr. Jung served as the Chief Medical Officer at Delenex Therapeutics AG. He spent 13 years at Novartis and served as its Head of Translational Medicine for The European Union. A board Certified Dermatologist, he has led research work in immunology at the Novartis Research Institute in Vienna, Austria, then spent nine years at Novartis in Basel. In January 2008, he took the leadership of the Ilaris(R) development team, until its first marketing approval in 2009. Since then, he was part of the senior leadership team at the Novartis Institute for Biomedical Research (NIBR), as EU Head of Translational Medicine. He is an Associate Professor for Dermatology at the University of G??ttingen, Germany.